4568.T - Daiichi Sankyo Company, Limited
NEXT EARNINGS:
Apr 23, 2026
EPS Est: $59.74
|
Rev Est: $594.1B
Price:
--
--
Market Cap:
5.51T
Volume:
2,675,200
Avg Volume:
8,379,849
52 Week Range:
2684-4178
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
-0.33
Last Dividend:
$78.00
Exchange:
JPX
Country:
JP
Employees:
18,726
IPO Date:
2000-01-04
EPS (TTM):
155.96
P/E Ratio:
22.51
Revenue (TTM):
1.89T
Total Assets:
3.46T
Total Debt:
155.89B
Cash & Equiv:
367.46B
Rev Growth (5Y):
14.0%
EPS Growth (5Y):
18.6%
FCF Growth (5Y):
N/A
ROCE:
11.5%
Debt/Equity:
0.10
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-01-30 | $46.21 | $38.66 | +19.5% | $558.1B | $543.1B | +2.8% |
| 2025-10-29 | $25.56 | $46.73 | -45.3% | $500.8B | $516.5B | -3.0% |
| 2025-07-29 | $47.18 | $35.06 | +34.6% | $474.6B | $472.2B | +0.5% |
| 2025-04-23 | $44.31 | $18.62 | +138.0% | $518.7B | $470.7B | +10.2% |
| 2025-01-29 | $32.32 | $32.52 | -0.6% | $484.8B | $467.3B | +3.8% |
| 2024-10-31 | $32.23 | $26.40 | +22.1% | $446.6B | $453.6B | -1.5% |
| 2024-07-31 | $44.60 | $23.30 | +91.4% | $436.2B | $371.0B | +17.6% |
| 2024-04-25 | $19.38 | $7.56 | +156.3% | $428.4B | $420.4B | +1.9% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.89T | 1.60T | 1.28T | 1.04T | 962.52B | 981.79B | 929.72B | 960.20B | 955.12B | 986.45B | 919.37B | 1.12T |
| Net Income | 295.76B | 200.73B | 109.19B | 66.97B | 75.96B | 129.07B | 93.41B | 60.28B | 53.47B | 82.28B | 322.12B | 60.94B |
| EPS | 155.96 | 104.69 | 56.96 | 34.94 | 39.17 | 66.40 | 48.07 | 30.44 | 26.54 | 39.79 | 152.52 | 28.86 |
| Total Assets | 3.46T | 3.46T | 2.51T | 2.22T | 2.09T | 2.11T | 2.09T | 1.90T | 1.91T | 1.90T | 1.98T | 1.85T |
| Total Debt | 155.89B | 156.00B | 192.86B | 213.62B | 226.17B | 266.33B | 261.92B | 282.10B | 282.14B | 203.62B | 224.64B | 426.84B |
| Cash & Equivalents | 367.46B | 415.26B | 334.82B | 550.18B | 294.80B | 280.41B | 154.86B | 258.21B | 246.05B | 222.16B | 189.37B | 183.07B |
| Operating Cash Flow | 53.84B | 599.26B | 114.51B | 139.23B | 192.21B | 196.60B | 92.03B | 108.44B | 136.23B | 174.28B | 142.78B | 37.30B |
| Free Cash Flow | (62.42B) | 510.94B | 53.77B | 76.49B | 160.96B | 164.66B | 55.92B | 85.04B | 111.47B | 147.15B | 104.28B | (10.19B) |
| FCF per Share | -32.91 | 266.48 | 28.05 | 39.91 | 83.00 | 84.71 | 28.78 | 42.94 | 55.34 | 71.16 | 49.37 | -4.83 |
| Book Value | 1.62T | 1.69T | 1.45T | 1.35T | 1.27T | 1.31T | 1.25T | 1.13T | 1.18T | 1.23T | 1.30T | 979.93B |
| Cash & ST Investments | 713.97B | 876.56B | 607.56B | 778.62B | 629.74B | 520.02B | 560.37B | 594.37B | 798.21B | 714.73B | 374.71B | 506.23B |
| ROC Equity | 0.18 | 0.12 | 0.08 | 0.05 | 0.06 | 0.10 | 0.07 | 0.05 | 0.05 | 0.07 | 0.25 | 0.06 |